Genomics BioSci & Tech.Ltd Past Earnings Performance
Past criteria checks 0/6
Genomics BioSci & Tech.Ltd's earnings have been declining at an average annual rate of -47.8%, while the Biotechs industry saw earnings growing at 21.8% annually. Revenues have been growing at an average rate of 11% per year.
How Genomics BioSci & Tech.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TWSE:4195 Revenue, expenses and earnings (TWD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
738
-55
234
85
31 Dec 25
708
-39
233
82
30 Sep 25
608
-84
196
88
30 Jun 25
563
-178
189
89
31 Mar 25
524
-221
215
87
31 Dec 24
518
-223
209
89
30 Sep 24
465
-199
186
76
30 Jun 24
434
-158
167
71
31 Mar 24
415
-163
156
64
31 Dec 23
396
-168
145
56
30 Sep 23
401
-121
147
50
30 Jun 23
405
-75
148
44
31 Mar 23
412
-2
141
40
31 Dec 22
419
72
134
36
30 Sep 22
411
58
123
29
30 Jun 22
402
45
111
23
31 Mar 22
396
32
116
20
31 Dec 21
390
19
121
17
30 Sep 21
408
31
127
20
30 Jun 21
426
44
133
22
31 Mar 21
434
22
130
22
31 Dec 20
443
1
126
23
30 Sep 20
454
7
126
23
30 Jun 20
465
14
127
24
31 Mar 20
447
16
121
27
31 Dec 19
428
18
116
30
30 Sep 19
408
-1
117
33
30 Jun 19
388
-20
118
36
31 Mar 19
382
-28
121
41
31 Dec 18
375
-36
124
45
30 Sep 18
397
-31
131
50
30 Jun 18
418
-27
138
55
31 Mar 18
429
-31
140
50
31 Dec 17
440
-36
141
45
30 Sep 17
401
-45
137
38
30 Jun 17
362
-55
133
31
31 Mar 17
369
-50
131
30
31 Dec 16
376
-44
130
28
30 Sep 16
397
-37
124
25
30 Jun 16
418
-30
117
23
31 Mar 16
409
-30
111
21
31 Dec 15
401
-30
105
19
30 Sep 15
379
-31
103
18
Quality Earnings: 4195 is currently unprofitable.
Growing Profit Margin: 4195 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4195 is unprofitable, and losses have increased over the past 5 years at a rate of 47.8% per year.
Accelerating Growth: Unable to compare 4195's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4195 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.2%).
Return on Equity
High ROE: 4195 has a negative Return on Equity (-15.65%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/07 10:20
End of Day Share Price
2026/07/07 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genomics BioSci & Tech. Co.,Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.